Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients

Transfusion

Volumn 44, Issue 5, 2004, Pages 790-794

  Santagostino, E ^a   De Filippi, F ^a   Rumi, M G ^a   Rivi, M ^a   Colombo, Massimo ^a,b   Mannucci, P M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATIGUE; FEMALE; GENOTYPE; HEMOLYTIC ANEMIA; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS 1; HEPATITIS C VIRUS 2; HEPATITIS C VIRUS 3; HUMAN; HYPOTHYROIDISM; IMMUNE RESPONSE; LIVER BIOPSY; MALE; NEUTROPENIA; PATIENT SELECTION; RISK BENEFIT ANALYSIS; TREATMENT WITHDRAWAL; VIRUS INHIBITION;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 2342555596     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.03154.x     Document Type: Article

References (21)

1. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997; 350:1425-31.
2. Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002;100:1584-9.
3. Fried MW, Peter J, Hoots K, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology 2002;36:967-72.
4. Hanley JP, Jarvis LM, Andrew J, et al. Interferon treatment for chronic hepatitis C infections in hemophiliacs. Influence of virus load genotype and liver pathology on response. Blood 1996;87:1704-9.
5. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32.
7. Saracco G, Ciancio A, Olivero A, et al. A randomized 4-arm multicenter study of interferon α-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001;34:133-8.
8. The National Institutes of Health Consensus Development Conference. Management of hepatitis C. Hepatol 1997; 26:2S-10S.
9. Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol 2003;38(Suppl 1):S104-18.
10. Santagostino E, Rumi MG, Rivi M, et al. Hepatitis Study Group of the Association of Italian Hemophilia Centers. Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Blood 2002;99:1089-91.
11. Rumi MG, Santagostino E, Morfini M, et al. A multicenter controlled, randomized, open trial of interferon α2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. Blood 1997;89:3529-33.
12. Rumi MG, Del Ninno E, Parravicini ML, et al. Long-term titrated recombinant interferon-α 2a in chronic hepatitis C: a randomized controlled trial. J Viral Hep 1995;2: 73-6.
13. Kernoff PBA, Lee CA, Karayiannis P, Thomas HC. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985;60:469-79.
14. Sauleda S, Esteban JI, Altisent C, et al. Treatment with interferon plus ribavirin in anti-HIV negative patients with congenital coagulation disorders and chronic hepatitis C. Thromb Haemost 2000;83:807-10.
15. Mangia A, Santoro R, Piattelli M, et al. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. J Hepatol 2002;37:109-16.
16. Pol S, Nalpas B, Bourliére M, et al. Combination of ribavirin and interferon-alpha surpasses high doses of interferon-alpha alone in patients with genotype-1b-related chronic hepatitis C. Hepatology 2000;31:1338-44.
17. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis. N Engl J Med 2000;343: 1666-72.
18. Manns MP, McHutchison IG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
19. Rakov NE. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C. N Engl J Med 2003;348:259-60.
20. Pawlotsky JM, Roudot-Thoraval F, Bastie A, et al. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis 1996;174:1-7.
21. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.